TriSalus Life Sciences, Inc. (TLSI) Current Ratio
- Current ratio · latest quarter: Value 5.35×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 5.35× | Current assets / current liabilities. $59.74M ÷ $11.17M ≈ 5.35× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 59.74M USD | Assets, Current |
| Current obligations | 11.17M USD | Liabilities, Current |
| Cash and equivalents | 46.29M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 6.46M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 4.21M USD | Inventory, Net |
| Payables | (m) | |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $59.74M | $11.17M | $46.29M | (m) | $6.46M | $4.21M | (m) | (m) | 5.35× |
| 2026-03-31 | $68.14M | $11.79M | $56.55M | (m) | $5.21M | $3.78M | (m) | (m) | 5.78× |
| 2025-12-31 | $32.24M | $11.50M | $20.44M | (m) | $6.56M | $3.08M | (m) | (m) | 2.80× |
| 2025-09-30 | $33.33M | $10.91M | $22.69M | (m) | $5.00M | $3.28M | (m) | (m) | 3.05× |
| 2025-06-30 | $38.08M | $9.32M | $26.49M | (m) | $5.57M | $3.81M | (m) | (m) | 4.08× |
| 2025-03-31 | $25.10M | $11.75M | $13.00M | (m) | $5.45M | $4.16M | (m) | (m) | 2.14× |
| 2024-12-31 | $20.67M | $10.23M | $8.53M | (m) | $5.09M | $4.05M | (m) | (m) | 2.02× |
| 2024-09-30 | $23.81M | $9.92M | $11.29M | (m) | $4.91M | $4.00M | (m) | (m) | 2.40× |
| 2024-06-30 | $27.94M | $12.00M | $16.48M | (m) | $4.71M | $3.44M | (m) | (m) | 2.33× |
| 2024-03-31 | $13.19M | $14.39M | $3.97M | (m) | $4.28M | $2.91M | (m) | (m) | 0.92× |
| 2023-12-31 | $20.86M | $14.69M | $11.78M | (m) | $3.55M | $2.54M | (m) | (m) | 1.42× |
| 2023-09-30 | $29.04M | $9.30M | $21.38M | (m) | $3.05M | $1.63M | (m) | (m) | 3.12× |
| 2023-06-30 | $161.45K | $6.03M | $103.97K | (m) | (m) | (m) | (m) | (m) | 0.03× |
| 2023-03-31 | $300.88K | $4.66M | $136.80K | (m) | (m) | (m) | (m) | (m) | 0.06× |
| 2022-12-31 | $17.21M | $32.36M | $9.41M | (m) | $1.56M | $1.47M | (m) | (m) | 0.53× |
| 2022-09-30 | $306.22K | $1.91M | $207.60K | (m) | (m) | (m) | (m) | (m) | 0.16× |
| 2022-06-30 | $266.43K | $1.74M | $69.18K | (m) | (m) | (m) | (m) | (m) | 0.15× |
| 2022-03-31 | $346.81K | $2.08M | $50.93K | (m) | (m) | (m) | (m) | (m) | 0.17× |
| 2021-12-31 | $525.88K | $1.60M | $200.88K | (m) | (m) | (m) | (m) | (m) | 0.33× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |